Compare Biogen Inc (BIIB) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Philip Morris International Inc. — how do they compare? Biogen Inc trades at $190.99 (market cap $28.34B), while Philip Morris International Inc. trades at $176.37 (market cap $274.23B). The key difference: Philip Morris International Inc. is far larger — about 9.7× Biogen Inc's market cap, and Philip Morris International Inc. pays a 3.34% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PM | |
|---|---|---|
Market Cap | $28.34B | $274.23B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $191.86 |
52-Week Low | $122.68 | $144.33 |
Enterprise Value | $30.62B | $320.73B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Philip Morris International (PM) trades at $180.19, down 0.79% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $194.00. The company reported strong Q1 2026 EPS of $1.96, beating expectations, and maintains robust profitability with a 26.74% net income margin. Recent news includes a $500 million impairment charge in Q2 2026 and CFO succession plans, while cash flow trends show stable operations.
The stock presents a favorable risk-reward profile with upside to analyst targets, driven by earnings beats and brand strength, though risks include currency volatility, regulatory pressures, and consumer spending constraints highlighted in recent Reuters and WSJ reports. Long-term investors may find value in its dividend yield and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
